Fintel reports that on January 7, 2026, Oppenheimer initiated coverage of Design Therapeutics (NasdaqGS:DSGN) with a Outperform recommendation.
Analyst Price Forecast Suggests 35.88% Upside
As of December 21, 2025, the average one-year price target for Design Therapeutics is $11.98/share. The forecasts range from a low of $7.07 to a high of $15.75. The average price target represents an increase of 35.88% from its latest reported closing price of $8.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Design Therapeutics is 144MM, an increase of 436,354.55%. The projected annual non-GAAP EPS is -1.00.
What is the Fund Sentiment?
There are 212 funds or institutions reporting positions in Design Therapeutics. This is an decrease of 4 owner(s) or 1.85% in the last quarter. Average portfolio weight of all funds dedicated to DSGN is 0.08%, an increase of 53.76%. Total shares owned by institutions decreased in the last three months by 0.18% to 36,867K shares. 
The put/call ratio of DSGN is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Sr One Capital Management holds 6,526K shares representing 11.46% ownership of the company. No change in the last quarter.
Logos Global Management holds 3,655K shares representing 6.42% ownership of the company. In its prior filing, the firm reported owning 4,218K shares , representing a decrease of 15.39%. The firm increased its portfolio allocation in DSGN by 56.86% over the last quarter.
Point72 Asset Management holds 3,341K shares representing 5.86% ownership of the company. In its prior filing, the firm reported owning 1,807K shares , representing an increase of 45.90%. The firm increased its portfolio allocation in DSGN by 252.09% over the last quarter.
Frazier Life Sciences Management holds 1,954K shares representing 3.43% ownership of the company. No change in the last quarter.
Tang Capital Management holds 1,781K shares representing 3.13% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
